SMMT ▲ +0.7% - Summit Therapeutics Inc.
$SMMT Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma
19-OCT-2026 07:01 AM ET
Share this post
More filings for $SMMT
SMMT ▲ +0.3% - Summit Therapeutics Inc.Oct 5, 2026SMMT ▲ +20.0% - Summit Therapeutics Inc.Sep 29, 2026SMMT ▲ +3.6% - Summit Therapeutics Inc.Sep 13, 2026SMMT ▲ +3.9% - Summit Therapeutics Inc.Sep 9, 2026SMMT ▲ +6.4% - Summit Therapeutics Inc.Sep 2, 2026
View full $SMMT filing history →💬 Comments
Loading comments…
Leave a comment